Orchid Chemicals & Pharmaceuticals is currently trading at Rs 208.95, up by 6.25 points or 3.08% from its previous closing of Rs 202.70 on the BSE.
The scrip opened at Rs 204.00 and has touched a high and low of Rs 213.00 and Rs 204.00 respectively. So far 266772 shares were traded on the counter.
The BSE group 'B' stock of face value Rs 10 has touched a 52 week high of Rs 344.40 on 26-Oct-2010 and a 52 week low of Rs 165.00 on 09-Aug-2011.
Last one week high and low of the scrip stood at Rs 213.00 and Rs 175.10 respectively. The current market cap of the company is Rs 1427.86 crore.
The promoters holding in the company stood at 30.53% while Institutions and Non-Institutions held 20.15% and 44.75% respectively.
Orchid Chemicals & Pharmaceuticals’ (Orchid) Cephalosporin API manufacturing plant located in Alathur at Chennai has been re-opened and production activity will commenced immediately. The Alathur plant that had earlier received a closure notice from the Tamil Nadu Pollution Control Board (TNPCB) has now been cleared and production activities will commence immediately.
Orchid is a pharmaceutical company engaged in development and manufacture of active pharmaceutical ingredients (APIs) and finished dosage forms. It is also engaged in research of new drugs. The company was incorporated in the year 1992 as a 100% export-oriented unit (EOU).
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1808.80 |
| Dr. Reddys Lab | 1273.95 |
| Cipla | 1393.10 |
| Zydus Lifesciences | 1112.30 |
| Lupin | 2275.30 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: